Skip to content

Efficacy of Dexpanthenol in Thermic Erythema

Evaluation of the Effect of Bepanthen Burn Relief Foam Spray New Formula on a Thermic Erythema. Equivalence Trial. Intra-individual Design.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00839462
Enrollment
55
Registered
2009-02-09
Start date
2007-09-30
Completion date
2007-09-30
Last updated
2013-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythema

Keywords

Thermal Erythema, Dexpanthenol, Erythema, Efficacy

Brief summary

The study focuses to prove the equivalent efficacy of two different Dexpanthenol formulations.

Interventions

2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter

2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter

Sponsors

Bayer
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects * Phototype: I to IV according to Fitzpatrick scale

Exclusion criteria

* Pregnant or nursing women * Subjects registered as being in exclusion period in the French Health Minister file of subjects * Subjects with known allergy to cosmetics, skin care products, or topical drugs, a sensitivity related to any component of any formulations being tested

Design outcomes

Primary

MeasureTime frame
Global sum of scores for evaluating the cooling/soothing effect evaluated after first and second application2 min, 5 min, 10 min, 15 min

Secondary

MeasureTime frame
Skin temperature2 min, 5 min, 10 min
Evaluation of the cooling/soothing effect (scores) after first and second application2 min, 5min, 10 min, 15 min
Evaluation of the foam covering properties after first application2 min, 5 min, 10 min, 15 min
Incidence of adverse eventsFPFV - LPLV

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026